Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group-Reference-Cited by-同舟云学术

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

Published:2008-07 Issue:1 Volume:110 Page:65-70
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Miller David Scott,Blessing John A.,Bodurka Diane C.,Bonebrake Albert J.,Schorge John O.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference59 articles.

1. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Phase II study of the Gynecologic Oncology Group;Thigpen;Cancer,1981

2. A Phase II study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix. A Gynecologic Oncology Group study;Sutton;Invest New Drugs,1989

3. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study;Sutton;Gynecol Oncol,1993

4. A Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix. A gynecologic oncology group study;Bloss;J Clin Oncol,2002

5. A phase II trial of 5-fluorouracil and high-dose leucovorin in advanced or recurrent squamous cell carcinoma of the cervix;Look;Am J Clin Oncol,1996

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis;Frontiers in Immunology;2024-03-18

2. Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement;Gynecologic Oncology;2023-12

3. The evolving landscape of antibody-drug conjugates in gynecologic cancers;Cancer Treatment Reviews;2023-05

4. Systemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival;Critical Reviews in Oncology/Hematology;2023-03

5. Tratamiento del cáncer de cuello uterino en estadio III y IV;EMC - Ginecología-Obstetricia;2023-02